ReutersCodex · 实盘不做把握 5/10
北京时间·🕒 发布 05:12:43时区推断·⟳ 抓取 05:17:57·⚡ 决策 07-10 05:21:15 +3m18s·109.9 天前
Bausch + Lomb 的 BL1107 青光眼滴眼液二期试验未达主要终点并停止开发
事件方向对 Bausch + Lomb（BLCO.US）为利空：BL1107 原被公司列为约2031年上市、峰值销售约8亿美元的潜在管线，停止开发削弱远期管线叙事。
📄 原文Reuters↗ 原文
Bausch + Lomb (BLCO.TO) said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of repli…
不做 Bausch + Lomb（BLCO.US）
事件对BLCO.US方向偏空，但属于远期管线失败、非当期收入冲击；默认不开空仓且行情未确认可借券，盘后已有初步反应，因此不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司此前在R&D teach-in中专门讨论BL1107和Elios，说明BL1107作为青光眼管线已被投资者预期。
- 1Q26材料显示BL1107等临床招募推进，同时公司上调FY26收入至54.20亿至55.20亿美元区间，短期业绩支撑不依赖BL1107。
- Reuters报道Bausch + Lomb称BL1107未能复制小型研究中的视觉功能改善，将停止开发该青光眼滴眼液。市场反应:Reuters称美股盘后下跌约2.8%。
- 2026-07-09 21:19 UTC市场反应Futu非一手行情工具显示BLCO.US常规收盘价16.73美元，较前收16.66美元涨0.42%；Reuters提到的盘后下跌未进入该常规收盘报价。市场反应:常规盘未反映盘后利空，盘后已有初步下跌。
关键理由
- 事件方向对 Bausch + Lomb（BLCO.US）为利空：BL1107 原被公司列为约2031年上市、峰值销售约8亿美元的潜在管线，停止开发削弱远期管线叙事。
- 但这是中期临床失败且商业化时间远在2031年前后，对2026年收入没有直接冲击；公司1Q26指引收入约54.20亿至55.20亿美元，现有收入基数主要由Miebo、Xiidra、隐形眼镜和外科业务支撑，本事件从远期峰值销售预期8亿美元归零，而非短期收入/利润损失。
- 盘后已有约-2.8%的即时反应，且默认不开空仓；未取得可借券字段支持，不满足做空红线。
主要风险
- 若后续公司披露BL1107 SR或地理萎缩植入剂开发也受影响，利空可能扩大，但目前Reuters正文称公司仍将推进持续释放植入剂。
- 内部KB检索两次超时，未能补到付费研报对BL1107 rNPV或卖方模型权重的定量拆分。
反向证据
- 做空前查反向 · 来源 kb_search · 影响 weakens
内部KB检索超时，未取得可用反向证据结果；公开公司材料显示Miebo、Xiidra和FY26指引上调仍是近期正面支撑。
检索:Bausch Lomb recent positive catalyst Xiidra Miebo revenue guidance BLCO 原文 ↗ - 做空前查反向 · 来源 stock_quote · 日期 2026-07-09 · 影响 invalidates
行情返回真实价格和走势，但未返回enable_short_sell=true或可借券数量，不能满足做空红线。
检索:BLCO.US stock_quote full borrow short availability
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 995 字
Bausch + Lomb (BLCO.TO) said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of replicating visual function improvements observed in a smaller study.
The company said it will discontinue development of the eye drops for glaucoma-related vision improvement.
Here are further details: -
Bausch acquired the eye drop BL1107 through a buyout of Whitecap Biosciences last year.
U.S.-listed shares of the company were down 2.8% in extended trading.
The company said it will continue pursuing a sustained-release implant for the treatment of vision-threatening diseases, with a primary focus on geographic atrophy, an advanced, late stage of dry age-related macular degeneration.
Bausch expects clinical trials of the implant to begin in 2028.
"We’ve intentionally built a diversified pipeline ... not every program will succeed, but every study helps us make smarter decisions about where to invest,” said Bausch's medical chief Yehia Hashad.
The company said it will discontinue development of the eye drops for glaucoma-related vision improvement.
Here are further details: -
Bausch acquired the eye drop BL1107 through a buyout of Whitecap Biosciences last year.
U.S.-listed shares of the company were down 2.8% in extended trading.
The company said it will continue pursuing a sustained-release implant for the treatment of vision-threatening diseases, with a primary focus on geographic atrophy, an advanced, late stage of dry age-related macular degeneration.
Bausch expects clinical trials of the implant to begin in 2028.
"We’ve intentionally built a diversified pipeline ... not every program will succeed, but every study helps us make smarter decisions about where to invest,” said Bausch's medical chief Yehia Hashad.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。